CN110545670B - 噬菌体疗法 - Google Patents

噬菌体疗法 Download PDF

Info

Publication number
CN110545670B
CN110545670B CN201880016793.2A CN201880016793A CN110545670B CN 110545670 B CN110545670 B CN 110545670B CN 201880016793 A CN201880016793 A CN 201880016793A CN 110545670 B CN110545670 B CN 110545670B
Authority
CN
China
Prior art keywords
seq
phage
sequence
bacteriophage
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880016793.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110545670A (zh
Inventor
辛迪·费弗
海伦妮·布洛伊斯
马修·梅迪纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Airuitai Pharmaceutical Co
Original Assignee
Pherecydes Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pherecydes Pharma SA filed Critical Pherecydes Pharma SA
Priority to CN202111287234.5A priority Critical patent/CN114107220B/zh
Publication of CN110545670A publication Critical patent/CN110545670A/zh
Application granted granted Critical
Publication of CN110545670B publication Critical patent/CN110545670B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/40—Viruses, e.g. bacteriophages
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10231—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
CN201880016793.2A 2017-03-08 2018-03-07 噬菌体疗法 Active CN110545670B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111287234.5A CN114107220B (zh) 2017-03-08 2018-03-07 噬菌体疗法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305245.7A EP3372085A1 (en) 2017-03-08 2017-03-08 Phage therapy
EP17305245.7 2017-03-08
PCT/EP2018/055629 WO2018162566A1 (en) 2017-03-08 2018-03-07 Phage therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111287234.5A Division CN114107220B (zh) 2017-03-08 2018-03-07 噬菌体疗法

Publications (2)

Publication Number Publication Date
CN110545670A CN110545670A (zh) 2019-12-06
CN110545670B true CN110545670B (zh) 2021-11-23

Family

ID=58536918

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880016793.2A Active CN110545670B (zh) 2017-03-08 2018-03-07 噬菌体疗法
CN202111287234.5A Active CN114107220B (zh) 2017-03-08 2018-03-07 噬菌体疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111287234.5A Active CN114107220B (zh) 2017-03-08 2018-03-07 噬菌体疗法

Country Status (9)

Country Link
US (2) US11690885B2 (enExample)
EP (2) EP3372085A1 (enExample)
JP (2) JP7492337B2 (enExample)
CN (2) CN110545670B (enExample)
AU (2) AU2018231408B2 (enExample)
BR (1) BR112019018593A2 (enExample)
CA (1) CA3054874A1 (enExample)
IL (2) IL288099B (enExample)
WO (1) WO2018162566A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3372085A1 (en) 2017-03-08 2018-09-12 Pherecydes Pharma Phage therapy
WO2021146598A1 (en) * 2020-01-17 2021-07-22 Second Genome, Inc. Methods and compositions for treating atopic dermatitis
IL295408A (en) * 2020-02-18 2022-10-01 Armata Pharmaceuticals Inc Bacteriophage preparations for the treatment of staphylococcus infection
CZ309429B6 (cs) * 2020-03-31 2023-01-04 MB PHARMA s.r.o Lyofilizovaná testovací sada ke stanovení antimikrobiální biologické účinnosti fágových přípravků na bakterii Staphylococcus aureus
EP4132552A2 (en) * 2020-04-06 2023-02-15 Adaptive Phage Therapeutics, Inc. Method for treating implantable device infections
EP4337764A1 (en) * 2021-05-12 2024-03-20 Biomx Ltd. Staphylococcus bacteriophage and uses thereof
FR3161553A1 (fr) * 2024-04-30 2025-10-31 Hospices Civils De Lyon Compositions, en particulier, pharmaceutiques de bactériophages de la classe des Caudoviricetes , procédé et utilisations associés

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1690194A (zh) * 2004-04-26 2005-11-02 何俭 一株治疗金黄色葡萄球菌感染的噬菌体
WO2009087356A1 (en) * 2008-01-04 2009-07-16 Novolytics Limited Host range change phage
WO2010033546A1 (en) * 2008-09-16 2010-03-25 Intralytix, Inc. Novel staphylococcus aureus: bacteriophage and uses thereof
KR20130142820A (ko) * 2012-06-20 2013-12-30 한국외국어대학교 연구산학협력단 스태필로코커스 아우레우스의 박테리오파아지 및 그 용도
CN104845942A (zh) * 2015-04-22 2015-08-19 上海交通大学 可裂解多种耐药性金黄色葡萄球菌的噬菌体及其分离方法和用途
CN105567647A (zh) * 2015-11-06 2016-05-11 中国海洋大学 一株耐甲氧西林金黄色葡萄球菌噬菌体及其抑菌应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2103308A1 (de) * 2008-03-20 2009-09-23 PhytoLine GmbH Verfahren zur Herstellung eines Gemisches von Bakteriophagen und deren Verwendung für die Therapie von Antibiotika-resistenten Staphylococcen
US8043613B2 (en) * 2009-02-12 2011-10-25 Intron Biotechnology, Inc. Podoviriedae bacteriophage having killing activity specific to Staphylococcus aureus
EP2865383A1 (en) 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
EP2893933A1 (en) 2014-01-10 2015-07-15 Pherecydes Pharma Phage Therapy of E coli infections
EP3018201A1 (en) 2014-11-07 2016-05-11 Pherecydes Pharma Phage therapy
WO2017015652A1 (en) 2015-07-23 2017-01-26 Enbiotix, Inc. Bacteriophage for treating staphylococcus infections
EP3372085A1 (en) 2017-03-08 2018-09-12 Pherecydes Pharma Phage therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1690194A (zh) * 2004-04-26 2005-11-02 何俭 一株治疗金黄色葡萄球菌感染的噬菌体
WO2009087356A1 (en) * 2008-01-04 2009-07-16 Novolytics Limited Host range change phage
WO2010033546A1 (en) * 2008-09-16 2010-03-25 Intralytix, Inc. Novel staphylococcus aureus: bacteriophage and uses thereof
KR20130142820A (ko) * 2012-06-20 2013-12-30 한국외국어대학교 연구산학협력단 스태필로코커스 아우레우스의 박테리오파아지 및 그 용도
CN104845942A (zh) * 2015-04-22 2015-08-19 上海交通大学 可裂解多种耐药性金黄色葡萄球菌的噬菌体及其分离方法和用途
CN105567647A (zh) * 2015-11-06 2016-05-11 中国海洋大学 一株耐甲氧西林金黄色葡萄球菌噬菌体及其抑菌应用

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Genomic analysis ofStaphylococcusphage Stau2 isolated from medical specimen;Sue-Er Hsieh等;《Virus Genes》;20151226;第52卷(第1期);第107-116页 *
Staphylococcus phage S13" DNA,complete genome;Uchiyama J.等;《EBML Database》;20111222;Accession No. AB626963 *
Staphylococcus phage SA11,complete genome;Kim M.S.等;《EBML Database》;20120801;Accession No.JX194239 *
Staphylococcus phage SCH1,complete genome;Aleshkin A.V.等;《EBML Database》;20161125;Accession No.KY000084 *
Staphylococcus phage StAP1,complete genome;Senevirathne A.N.等;《EBML Database》;20170120;Accession No.KX532239 *
Staphylococcus phage Stau2,complete genome;Hsieh S. E.等;《EBML Database》;20160107;Accession No.KP881332 *
Staphylococcus phage vB_SauM_Remus,complete genome;Vandersteegen K.等;《EBML Database》;20130815;Accession No.JX846612 *
The Staphylococci Phages Family: An Overview;Marie Deghorain;《Viruses》;20121223;第4卷(第12期);第3316-3335页 *
Vandersteegen K.等.Staphylococcus phage vB_SauM_Remus,complete genome.《EBML Database》.2013,Accession No.JX846613. *
噬菌体及其裂解酶控制金黄色葡萄球菌的研究进展;李慧一等;《微生物与感染》;20130925;第8卷(第3期);第174-180页 *

Also Published As

Publication number Publication date
IL288099A (en) 2022-01-01
CN114107220A (zh) 2022-03-01
US12280080B2 (en) 2025-04-22
US20200030392A1 (en) 2020-01-30
AU2018231408B2 (en) 2023-07-27
JP7492337B2 (ja) 2024-05-29
CA3054874A1 (en) 2018-09-13
EP3592150A1 (en) 2020-01-15
WO2018162566A1 (en) 2018-09-13
IL268905A (en) 2019-10-31
AU2018231408A1 (en) 2019-09-12
JP2024105630A (ja) 2024-08-06
JP2020510024A (ja) 2020-04-02
IL268905B (en) 2021-12-01
AU2023251526A1 (en) 2023-11-16
CN114107220B (zh) 2025-01-10
BR112019018593A2 (pt) 2020-04-28
EP3372085A1 (en) 2018-09-12
CN110545670A (zh) 2019-12-06
US11690885B2 (en) 2023-07-04
IL288099B (en) 2022-07-01
US20240024391A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
DK3209381T3 (en) COMPOSITIONS COMPREHENSIVE BAKERY STUES
RU2725726C2 (ru) Бактериофаги, фаговые пептиды и способы их применения
CN110545670B (zh) 噬菌体疗法
CN108359643B (zh) 新型金黄色葡萄球菌噬菌体及其组合物和应用
KR102360880B1 (ko) 황색포도상구균 유래 점보박테리오파지 PALS2의 엔도라이신 LysPALS21
AU2025203392A1 (en) Therapeutic bacteriophage compositions
KR20170063879A (ko) 류머티스성 관절염용 바이오마커 및 이의 용도
CN112243377A (zh) 用于治疗和预防细菌相关的癌症的噬菌体
KR20240021274A (ko) 반코마이신 내성 장구균에 대한 박테리오파지
AU2012335397B2 (en) Novel bacteriophages
AU2018256922B2 (en) Targeted gene disruption methods and immunogenic compositions
KR101993123B1 (ko) 신규한 병원성 대장균 특이 박테리오파지 eco5 및 이를 포함하는 항균 조성물
KR102432624B1 (ko) 신규한 스타필로코커스균 특이 박테리오파지 opt-sc01 및 이를 포함하는 항균 조성물
JP2001292771A (ja) アブラムシ共生バクテリアのゲノムｄｎａ
KR102334893B1 (ko) 신규한 캠필로박터균 특이 박테리오파지 opt-cj1 및 이를 포함하는 항균 조성물
KR102723118B1 (ko) 스타필로코커스균 특이 박테리오파지 kmsp1 및 이를 포함하는 항균 조성물
KR102418861B1 (ko) 포도상구균에 대한 사멸능을 갖는 박테리오파지
KR102066898B1 (ko) 신규한 장알균 특이 박테리오파지 ef5 및 이를 포함하는 항균 조성물
CN115397447A (zh) 用于治疗葡萄球菌感染的噬菌体组合物
HK40083362A (en) Bacteriophage compositions for treating staphylococcus infection
CN114410591A (zh) 一种耐酸耐高温的金黄色葡萄球菌噬菌体及其组合物、试剂盒及其应用
HK40042802A (en) Bacteriophage for treatment and prevention of bacteria-associated cancers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240417

Address after: lyon

Patentee after: Airuitai Pharmaceutical Co.

Country or region after: France

Address before: Fa Guoluomanweier

Patentee before: PHERECYDES PHARMA

Country or region before: France

TR01 Transfer of patent right